SOST and chronic kidney disease: The marked increase in P1NP levels (+41.2% at 6 mo) in the romosozumab group demonstrates the anabolic effect of sclerostin inhibition, suggesting that this mechanism remains effective despite the complex alterations in bone metabolism associated with CKD-MBD.14